Eli Lilly (LLY) stock in focus as an expert panel of the EU drug regulator declines to endorse its Alzheimer's drug Kisunla.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback